|
1
|
Richterová R, Jurečeková J, Evinová A,
Kolarovszki B, Benčo M, De Riggo J, Sutovský J, Mahmood S, Račay P
and Dobrota D: Most frequent molecular and immunohistochemical
markers present in selected types of brain tumors. Gen Physiol
Biophys. 33:259–279. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ricard D, Idbaih A, Ducray F, Lahutte M,
Hoang-Xuan K and Delattre JY: Primary brain tumours in adults.
Lancet. 379:1984–1996. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ahmed R, Oborski MJ, Hwang M, Lieberman FS
and Mountz JM: Malignant gliomas: Current perspectives in
diagnosis, treatment, and early response assessment using advanced
quantitative imaging methods. Cancer Manag Res. 6:149–170.
2014.PubMed/NCBI
|
|
5
|
Persano L, Rampazzo E, Basso G and Viola
G: Glioblastoma cancer stem cells: Role of the microenvironment and
therapeutic targeting. Biochem Pharmacol. 85:612–622. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pointer KB, Clark PA, Zorniak M, Alrfaei
BM and Kuo JS: Glioblastoma cancer stem cells: Biomarker and
therapeutic advances. Neurochem Int. 71:1–7. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schonberg DL, Lubelski D, Miller TE and
Rich JN: Brain tumor stem cells: Molecular characteristics and
their impact on therapy. Mol Aspects Med. 39:82–101. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jovčevska I, Kočevar N and Komel R: Glioma
and glioblastoma - how much do we (not) know? Mol Clin Oncol.
1:935–941. 2013.PubMed/NCBI
|
|
9
|
Tirapelli LF, Bolini PH, Tirapelli DP,
Peria FM, Becker AN, Saggioro FP and Carlotti CG Jr: Caspase-3 and
Bcl-2 expression in glioblastoma: An immunohistochemical study. Arq
Neuropsiquiatr. 68:603–607. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ohgaki H and Kleihues P: Genetic
alterations and signaling pathways in the evolution of gliomas.
Cancer Sci. 100:2235–2241. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Karsy M, Neil JA, Guan J, Mahan MA, Colman
H and Jensen RL: A practical review of prognostic correlations of
molecular biomarkers in glioblastoma. Neurosurg Focus. 38:E42015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bralten LBC and French PJ: Genetic
alterations in glioma. Cancers (Basel). 3:1129–1140. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kleihues P, Louis DN, Scheithauer BW,
Rorke LB, Reifenberger G, Burger PC and Cavenee WK: The WHO
classification of tumors of the nervous system. J Neuropathol Exp
Neurol. 61:215–229. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Barazzuol L, Jena R, Burnet NG, Jeynes JC,
Merchant MJ, Kirkby KJ and Kirkby NF: In vitro evaluation of
combined temozolomide and radiotherapy using X rays and high-linear
energy transfer radiation for glioblastoma. Radiat Res.
177:651–662. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Westhoff MA, Brühl O, Nonnenmacher L,
Karpel-Massler G and Debatin KM: Killing me softly-future
challenges in apoptosis research. Int J Mol Sci. 15:3746–3767.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Redmond KM, Wilson TR, Johnston PG and
Longley DB: Resistance mechanisms to cancer chemotherapy. Front
Biosci. 13:5138–5154. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Riffkin CD, Gray AZ, Hawkins CJ, Chow CW
and Ashley DM: Ex vivo pediatric brain tumors express Fas (CD95)
and FasL (CD95L) and are resistant to apoptosis induction. Neuro
Oncol. 3:229–240. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Krajewski S, Krajewska M, Ehrmann J,
Sikorska M, Lach B, Chatten J and Reed JC: Immunohistochemical
analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and
peripheral nervous system origin. Am J Pathol. 150:805–814.
1997.PubMed/NCBI
|
|
19
|
Klymenko T, Brandenburg M, Morrow C, Dive
C and Makin G: The novel Bcl-2 inhibitor ABT-737 is more effective
in hypoxia and is able to reverse hypoxia-induced drug resistance
in neuroblastoma cells. Mol Cancer Ther. 10:2373–2383. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kögel D, Fulda S and Mittelbronn M:
Therapeutic exploitation of apoptosis and autophagy for
glioblastoma. Anticancer Agents Med Chem. 10:438–449. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Portt L, Norman G, Clapp C, Greenwood M
and Greenwood MT: Anti-apoptosis and cell survival: A review.
Biochim Biophys Acta. 1813:238–259. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fulda S and Debatin KM: Extrinsic versus
intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene.
25:4798–4811. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Thomas S, Quinn BA, Das SK, Dash R, Emdad
L, Dasgupta S, Wang XY, Dent P, Reed JC, Pellecchia M, et al:
Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther
Targets. 17:61–75. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tchoghandjian A, Jennewein C, Eckhardt I,
Momma S, Figarella- Branger D and Fulda S: Smac mimetic promotes
glioblastoma cancer stem-like cell differentiation by activating
NF-κB. Cell Death Differ. 21:735–747. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sayers TJ: Targeting the extrinsic
apoptosis signaling pathway for cancer therapy. Cancer Immunol
Immunother. 60:1173–1180. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wong RSY: Apoptosis in cancer: From
pathogenesis to treatment. J Exp Clin Cancer Res. 30:872011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gaur U and Aggarwal BB: Regulation of
proliferation, survival and apoptosis by members of the TNF
superfamily. Biochem Pharmacol. 66:1403–1408. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Suen DF, Norris KL and Youle RJ:
Mitochondrial dynamics and apoptosis. Genes Dev. 22:1577–1590.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hervouet E, Cheray M, Vallette FM and
Cartron PF: DNA methylation and apoptosis resistance in cancer
cells. Cells. 2:545–573. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Labi V, Grespi F, Baumgartner F and
Villunger A: Targeting the Bcl-2-regulated apoptosis pathway by BH3
mimetics: A breakthrough in anticancer therapy? Cell Death Differ.
15:977–987. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kelly PN and Strasser A: The role of Bcl-2
and its pro-survival relatives in tumourigenesis and cancer
therapy. Cell Death Differ. 18:1414–1424. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Llambi F and Green DR: Apoptosis and
oncogenesis: Give and take in the BCL-2 family. Curr Opin Genet
Dev. 21:12–20. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim H, Tu HC, Ren D, Takeuchi O, Jeffers
JR, Zambetti GP, Hsieh JJ and Cheng EH: Stepwise activation of BAX
and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis.
Mol Cell. 36:487–499. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vogler M, Dinsdale D, Dyer MJ and Cohen
GM: Bcl-2 inhibitors: Small molecules with a big impact on cancer
therapy. Cell Death Differ. 16:360–367. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Galluzzi L, Maiuri MC, Vitale I, Zischka
H, Castedo M, Zitvogel L and Kroemer G: Cell death modalities:
Classification and pathophysiological implications. Cell Death
Differ. 14:1237–1243. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Degterev A, Boyce M and Yuan J: A decade
of caspases. Oncogene. 22:8543–8567. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yuan S and Akey CW: Apoptosome structure,
assembly, and procaspase activation. Structure. 21:501–515. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bender A, Opel D, Naumann I, Kappler R,
Friedman L, von Schweinitz D, Debatin KM and Fulda S: PI3K
inhibitors prime neuroblastoma cells for chemotherapy by shifting
the balance towards pro-apoptotic Bcl-2 proteins and enhanced
mitochondrial apoptosis. Oncogene. 30:494–503. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Adams JM and Cory S: The Bcl-2 apoptotic
switch in cancer development and therapy. Oncogene. 26:1324–1337.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Vogler M: Targeting BCL2 proteins for the
treatment of solid tumours. Adv Med. 2014:9436482014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cohen NA, Stewart ML, Gavathiotis E,
Tepper JL, Bruekner SR, Koss B, Opferman JT and Walensky LD: A
competitive stapled peptide screen identifies a selective small
molecule that overcomes MCL-1-dependent leukemia cell survival.
Chem Biol. 19:1175–1186. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Oltersdorf T, Elmore SW, Shoemaker AR,
Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges
J, Hajduk PJ, et al: An inhibitor of Bcl-2 family proteins induces
regression of solid tumours. Nature. 435:677–681. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Degterev A, Lugovskoy A, Cardone M, Mulley
B, Wagner G, Mitchison T and Yuan J: Identification of
small-molecule inhibitors of interaction between the BH3 domain and
Bcl-xL. Nat Cell Biol. 3:173–182. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tse C, Shoemaker AR, Adickes J, Anderson
MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, et
al: ABT-263: A potent and orally bioavailable Bcl-2 family
inhibitor. Cancer Res. 68:3421–3428. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Reed JC, Meister L, Tanaka S, Cuddy M, Yum
S, Geyer C and Pleasure D: Differential expression of bcl2
protooncogene in neuroblastoma and other human tumor cell lines of
neural origin. Cancer Res. 51:6529–6538. 1991.PubMed/NCBI
|
|
47
|
Song JH, Kandasamy K, Zemskova M, Lin YW
and Kraft AS: The BH3 mimetic ABT-737 induces cancer cell
senescence. Cancer Res. 71:506–515. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Cichowski K and Hahn WC: Unexpected pieces
to the senescence puzzle. Cell. 133:958–961. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chen S, Dai Y, Harada H, Dent P and Grant
S: Mcl-1 down-regulation potentiates ABT-737 lethality by
cooperatively inducing Bak activation and Bax translocation. Cancer
Res. 67:782–791. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
van Delft MF, Wei AH, Mason KD, Vandenberg
CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, et
al: The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and
efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
Cancer Cell. 10:389–399. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kozopas KM, Yang T, Buchan HL, Zhou P and
Craig RW: MCL1, a gene expressed in programmed myeloid cell
differentiation, has sequence similarity to BCL2. Proc Natl Acad
Sci USA. 90:3516–3520. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Varin E, Denoyelle C, Brotin E,
Meryet-Figuière M, Giffard F, Abeilard E, Goux D, Gauduchon P,
Icard P and Poulain L: Downregulation of Bcl-xL and
Mcl-1 is sufficient to induce cell death in mesothelioma cells
highly refractory to conventional chemotherapy. Carcinogenesis.
31:984–993. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Li RY, Chen LC, Zhang HY, Du WZ, Feng Y,
Wang HB, Wen JQ, Liu X, Li XF, Sun Y, et al: MiR-139 inhibits Mcl-1
expression and potentiates TMZ-induced apoptosis in glioma. CNS
Neurosci Ther. 19:477–483. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zubor P, Hatok J, Moricova P, Kapustova I,
Kajo K, Mendelova A, Sivonova MK and Danko J: Gene expression
profiling of histologically normal breast tissue in females with
human epidermal growth factor receptor 2 positive breast cancer.
Mol Med Rep. 11:1421–1427. 2015.PubMed/NCBI
|
|
55
|
Zubor P, Hatok J, Galo S, Dokus K,
Klobusiakova D, Danko J and Racay P: Anti-apoptotic and
pro-apoptotic gene expression evaluated from eutopic endometrium in
the proliferative phase of the menstrual cycle among women with
endometriosis and healthy controls. Eur J Obstet Gynecol Reprod
Biol. 145:172–176. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Blahovcova E, Richterova R, Kolarovszki B,
Dobrota D, Racay P and Hatok J: Apoptosis-related gene expression
in tumor tissue samples obtained from patients diagnosed with
glioblastoma multiforme. Int J Mol Med. 36:1677–1684.
2015.PubMed/NCBI
|
|
57
|
Vitucci M, Hayes DN and Miller CR: Gene
expression profiling of gliomas: Merging genomic and
histopathological classification for personalised therapy. Br J
Cancer. 104:545–553. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Cancer Genome Atlas Research Network, .
Comprehensive genomic characterization defines human glioblastoma
genes and core pathways. Nature. 455:1061–1068. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Mosmann T: Rapid colorimetric assay for
cellular growth and survival: Application to proliferation and
cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Shiozaki EN and Shi Y: Caspases, IAPs and
Smac/DIABLO: Mechanisms from structural biology. Trends Biochem
Sci. 29:486–494. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Shi Y: Mechanisms of caspase activation
and inhibition during apoptosis. Mol Cell. 9:459–470. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Verhagen AM, Coulson EJ and Vaux DL:
Inhibitor of apoptosis proteins and their relatives: IAPs and other
BIRPs. Genome Biol. 2:REVIEWS30092001. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT,
Liu B and Bao JK: Programmed cell death pathways in cancer: A
review of apoptosis, autophagy and programmed necrosis. Cell
Prolif. 45:487–498. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Wen X, Lin ZQ, Liu B and Wei YQ:
Caspase-mediated programmed cell death pathways as potential
therapeutic targets in cancer. Cell Prolif. 45:217–224. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Ghavami S, Hashemi M, Ande SR, Yeganeh B,
Xiao W, Eshraghi M, Bus CJ, Kadkhoda K, Wiechec E, Halayko AJ, et
al: Apoptosis and cancer: Mutations within caspase genes. J Med
Genet. 46:497–510. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Kurokawa M and Kornbluth S: Caspases and
kinases in a death grip. Cell. 138:838–854. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Tagscherer KE, Fassl A, Campos B, Farhadi
M, Kraemer A, Böck BC, Macher-Goeppinger S, Radlwimmer B, Wiestler
OD, Herold-Mende C, et al: Apoptosis-based treatment of
glioblastomas with ABT-737, a novel small molecule inhibitor of
Bcl-2 family proteins. Oncogene. 27:6646–6656. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Wei B, Wang L, Du C, Hu G, Wang L, Jin Y
and Kong D: Identification of differentially expressed genes
regulated by transcription factors in glioblastomas by
bioinformatics analysis. Mol Med Rep. 11:2548–2554. 2015.PubMed/NCBI
|
|
69
|
Stancheva G, Goranova T, Laleva M,
Kamenova M, Mitkova A, Velinov N, Poptodorov G, Mitev V, Kaneva R
and Gabrovsky N: IDH1/IDH2 but not TP53 mutations predict prognosis
in Bulgarian glioblastoma patients. BioMed Res Int.
2014:6547272014. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
England B, Huang T and Karsy M: Current
understanding of the role and targeting of tumor suppressor p53 in
glioblastoma multiforme. Tumour Biol. 34:2063–2074. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Li J: Di Ch, Mattox AK, Wu L and Adamson
DC: The future role of personalized medicine in the treatment of
glioblastoma multiforme. Pharm Genomics Pers Med. 3:111–127.
2010.
|
|
72
|
Elmore S: Apoptosis: A review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Song T, Chai G, Liu Y, Xie M, Chen Q, Yu
X, Sheng H and Zhang Z: Mechanism of synergy of BH3 mimetics and
paclitaxel in chronic myeloid leukemia cells: Mcl-1 inhibition. Eur
J Pharm Sci. 70:64–71. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Nakano K and Vousden KH: PUMA, a novel
proapoptotic gene, is induced by p53. Mol Cell. 7:683–694. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Ito H, Kanzawa T, Miyoshi T, Hirohata S,
Kyo S, Iwamaru A, Aoki H, Kondo Y and Kondo S: Therapeutic efficacy
of PUMA for malignant glioma cells regardless of p53 status. Hum
Gene Ther. 16:685–698. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Maier JK, Lahoua Z, Gendron NH, Fetni R,
Johnston A, Davoodi J, Rasper D, Roy S, Slack RS, Nicholson DW, et
al: The neuronal apoptosis inhibitory protein is a direct inhibitor
of caspases 3 and 7. J Neurosci. 22:2035–2043. 2002.PubMed/NCBI
|
|
77
|
Holcik M, Thompson CS, Yaraghi Z, Lefebvre
CA, MacKenzie AE and Korneluk RG: The hippocampal neurons of
neuronal apoptosis inhibitory protein 1 (NAIP1)-deleted mice
display increased vulnerability to kainic acid-induced injury. Proc
Natl Acad Sci USA. 97:2286–2290. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Mercer EA, Korhonen L, Skoglösa Y, Olsson
PA, Kukkonen JP and Lindholm D: NAIP interacts with hippocalcin and
protects neurons against calcium-induced cell death through
caspase-3-dependent and -independent pathways. EMBO J.
19:3597–3607. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Saggioro FP, Neder L, Stávale JN,
Paixão-Becker AN, Malheiros SM, Soares FA, Pittella JE, Matias CC,
Colli BO, Carlotti CG Jr, et al: Fas, FasL, and cleaved caspases 8
and 3 in glioblastomas: A tissue microarray-based study. Pathol Res
Pract. 210:267–273. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Siegelin MD, Gaiser T and Siegelin Y: The
XIAP inhibitor Embelin enhances TRAIL-mediated apoptosis in
malignant glioma cells by down-regulation of the short isoform of
FLIP. Neurochem Int. 55:423–430. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Ashley DM, Riffkin CD, Muscat AM, Knight
MJ, Kaye AH, Novak U and Hawkins CJ: Caspase 8 is absent or low in
many ex vivo gliomas. Cancer. 104:1487–1496. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Peter ME and Krammer PH: The
CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 10:26–35. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Konopleva M, Contractor R, Tsao T, Samudio
I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, et al:
Mechanisms of apoptosis sensitivity and resistance to the BH3
mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 10:375–388.
2006. View Article : Google Scholar : PubMed/NCBI
|
